The shadow of generic challenges has consistently loomed around copyright’s blockbuster drug, Viagra, triggering questions about the prospects of similar pharmaceutical investments. While initial years saw substantial returns, the patent lapse has opened the way for less expensive substitutes, likely reducing profitability and posing a real dange